Agenda | MedTech World Asia

Positioning HK as a launchpad into Mainland China, Southeast Asia, and beyond. Leaders explore why HK’s regulatory environment, capital markets, and GBA proximity make it uniquely suited for MedTech companies seeking regional scale.

Procurement, tendering, and reimbursement realities in China, Japan, Hong Kong, and beyond. Health system insiders and MedTech executives break down what it actually takes to get listed, funded, and adopted within Asian public healthcare frameworks.

How Southeast Asian MedTech funding trends diverge from US and European markets. This panel examines investor risk appetite, deal structures, due diligence expectations, and the cultural nuances that shape how capital flows to innovation in Asia.

Presenting Slot

This panel explores how AI is transforming complex health data—such as genomics, imaging, and real-world evidence—into actionable insights for more personalized care. Experts will discuss real-world applications, challenges, and how we can accelerate the shift toward delivering the right treatment to the right patient at the right time.

Leading APAC VCs and family offices discuss investment priorities, what’s attracting capital across the region, and what founders misunderstand about raising from Asian investors. A candid look at which sectors and geographies are generating the strongest interest.

Everyone talks about Hong Kong’s health innovation ecosystem from the policy and GBA angle. This panel asks the people actually building it: the investors funding it, the infrastructure and cloud players enabling it, and the clinicians translating it into care. What does it really take to move an idea from lab to patient here, and who’s carrying that weight?

Presenting Slot

Expanding across Asia is not a one-size-fits-all playbook. This session dives into the practical realities of entering and scaling across multiple APAC markets, covering regulatory sequencing, localization, partnerships, and go-to-market strategies needed to succeed in diverse healthcare systems.

Designing products for markets with varying connectivity, data regulation, and digital literacy. This panel explores how to build digital health solutions that work across Asia’s diverse infrastructure conditions, from tier-1 cities to rural populations.

Obesity can no longer be addressed through medication alone. The future will depend on the convergence of GLP-1 therapies, wearables, continuous health monitoring, AI-driven support, personalized prevention, stronger patient agency, and coordinated public policy. The keynote would also explore how China is increasingly treating obesity as a national priority, with government leadership and ecosystem-wide action, similar to the way major challenges such as sustainability and climate change are approached. The central message is simple: sustainable obesity management will require more than one drug or one device. It will require an integrated ecosystem combining medicine, technology, behaviour, and policy.

How the GBA policy framework, Shenzhen’s manufacturing base, and HK’s regulatory gateway create a unique launchpad for global MedTech companies. Panelists discuss practical strategies for navigating cross-border operations within the GBA.

What regional and international investors want to see before writing the cheque. Panelists walk through the milestones, metrics, and narratives that move a MedTech company from early-stage funding to a credible path toward public markets in Asia.

From diagnostics to therapeutics, what regional health systems are prioritising in women’s health. This panel examines the commercial opportunity, clinical evidence requirements, and cultural factors shaping FemTech adoption across Asian markets.

Presenting Slot

What separates funded startups from those that truly scale? Investors, founders, and accelerators share practical insights on validation, regulation, market entry, and execution across Asia.

When corporate investment makes more sense than VC for MedTech scale-up. This panel explores CVC relationships, strategic partnership structures, and non-dilutive funding options that let companies accelerate growth without sacrificing control.

From surgical platforms and robotic bronchoscopy to next-generation minimally invasive and remotely operated systems, medical robotics is expanding far beyond the traditional operating room. Which Asian markets are leading adoption, how are companies financing and scaling their expansion, and what does it take to build technologies that hospitals and clinicians will actually use? This panel will examine regulation, hospital adoption, clinical workflows, affordability, physician usability, and the competitive landscape across China, Hong Kong, Singapore, and the wider Asia-Pacific region.

Presenting Slot

India is rapidly emerging as a serious MedTech innovation hub. With a massive patient population, PLI manufacturing incentives, and a maturing CDSCO regulatory framework, this panel explores what it takes to enter, scale, or partner in India.

Depart from the hotel in Hong Kong and travel to Shenzhen Bay Port.

Visit Mindray and explore one of China’s leading MedTech companies.

Visit Alibaba Group and participate in discussions with representatives from the Ministry of Industry and Information Technology (MIIT) and leading MedTech companies, exploring potential collaboration and business opportunities.

Transfer back to Shenzhen Bay Port. Guests may either return to Hong Kong independently or remain in Shenzhen for leisure.